Biorce Raises €43.8 Million Series A To Speed Up AI-Powered Clinical Trials

The round includes new investment from DST Global Partners, with existing investors Norrsken VC and YZR Capital increasing their support, alongside Mustard Seed Maze. Notable angel investors joining the round include Arthur Mensch (Mistral AI), Albert Nieto (Seedtag), Paulo Rosado (OutSystems), and Nik Storonsky (Revolut).

Biorce says this is the largest Series A ever in the Iberian HealthTech and AI sector. Over the past year, the company raised €8.5 million in Seed funding a €3.5 million round in November 2024 and a €5 million extension from Norrsken VC in summer 2025 followed by the €43.8 million Series A. With this latest round, Biorce has raised over €50.6 million ($60 million) in total.

Pedro Coelho, CEO of Biorce, commented, “This $52 million (€43.8 million) round reflects both the scale of the problem we are addressing and the market’s confidence in our vision. Clinical trial delays and inefficiencies cost time, money and ultimately lives. Our mission is to make trials faster, more reliable, and more accessible, so patients can benefit from new treatments sooner. The speed at which we have raised capital since our last round in July 2025 is a strong validation of our technology, our team, and the impact we can generate.”

Biorce, founded in 2024, aims to transform the clinical trial industry by cutting costs by over 50% and helping life-saving treatments reach patients faster.

Read Also - iAltA Holdings Announces Acquisition Of BridgeFT

Clinical trials typically take nearly 11 years and cost €5.2 billion ($6.2 billion) per drug with 57% facing costly protocol amendments that delay progress. Overall, clinical trial management accounts for an estimated €101.2 billion ($120 billion) in global annual spending. Protocol amendments alone often halt patient recruitment for six weeks and add €500k–€1 million, creating billions in industry-wide costs.

A key challenge is that teams struggle to justify trial design decisions to regulators like the FDA and EMA, leading to reviews, delays and additional amendments.

To address this, Biorce developed Aika, an AI-powered platform that shortens trial preparation and reduces protocol amendments, accelerating therapy development by up to 50%. Built on data from around 1 million clinical trials, Aika helps pharmaceutical companies, biotech firms and CROs design better trials faster without compromising scientific rigor or patient safety.

The platform streamlines protocol development, site selection and feasibility assessments, reducing complexity, speeding timelines and improving operational efficiency.

Discussing how Aika differs from other AI platforms in pharma, the company mentioned, “Most AI solutions ask you to trust algorithms you can’t explain. We built the opposite. Every Aika recommendation comes with complete documentation that you can defend before any regulatory authority. Our “human-in-the-loop” approach ensures the expert stays in control.”

Biorce says Aika is already in use across several therapeutic areas, including oncology, neurology, and rare diseases. Its therapy-agnostic design enables the company to apply AI across a broad range of clinical programs.

The new funding will support Biorce’s international expansion, particularly into the United States including the upcoming launch of a development and R&D hub in Austin, Texas.

The capital will also help Biorce grow its team to around 250 employees by the end of 2026, focusing on engineering and commercial roles, while accelerating product development. The company reported ending last year approximately 200% above its revenue target.

“The platform is already seeing strong global demand, proving it can materially reduce timelines and costs for pharma and, more importantly, bring new treatments to patients faster than previously possible. That’s why we’re excited to double down on our investment. Their expansion into the U.S. is a natural next step and further cements the company’s trajectory toward becoming a category-defining force in clinical research,” said Tove Larsson, General Partner at Norrsken VC, Board Member.

In Q1 2026, Biorce will focus on enhancing Aika’s protocol intelligence and adding new modules, including contract management and negotiation tools. Additional features will support budget discussions and operational planning. To accommodate its next growth phase, the company is moving to larger offices in Barcelona.

About Biorce

Biorce is a Barcelona-based HealthTech company transforming clinical trials with AI. Its platform, Aika, accelerates drug development, reduces protocol delays and improves operational efficiency. By cutting costs and timelines, Biorce helps life-saving treatments reach patients faster, reimagining how cures are developed and clinical trials are run.